Bruker Corporation (BRKR)
NEUTRALFundamental
40
Kurs
$57.28
Marktkapitalisierung
$8.94B
Teil 1 · Was das Unternehmen wert ist
Übersicht
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR technologies; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; services for transcriptional profiling and multiomic analysis; superconducting materials, such as metallic low temperature superconductors; multifilament round and rectangular LTS wires in both monolithic and wire-in-channel formats; designs and manufactures Cuponal; metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation was founded in 1960 and is headquartered in Billerica, Massachusetts.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilanz & Liquidität
Umsatz
$3.50B
Letzte 12 Monate (bis 30.6.2026)
Nettogewinn
$-71M
Letzte 12 Monate (bis 30.6.2026)
Freier Cashflow
$43M
Gesamtes Eigenkapital
$2.46B
Gesamtverbindlichkeiten
$3.73B
Current Ratio
1.85
Zinsdeckungsgrad
0.50
Schulden/EBITDA
6.33
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$44.24
Aktueller Kurs
$57.28
Sicherheitsmarge
-29.5%
Innerer-Wert-Spanne
$28.76 - $59.73
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
-
ROE
-0.4%
P/B-Verhältnis
3.62
P/FCF
92.45
Bruttomarge
46.4%
ROIC
-0.5%
Rentabilitäts-Radar
Value Creation (Economic Moat)
ROIC
-0.5%
WACC
9.8%
ROIC − WACC
-10.3 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamentalanalyse-Kriterien
Bestanden (10)
- Price CAGR 10.89%
- Gross Margin 46.4%
- Debt/Equity ratio
- Positive Free Cash Flow
- Current Ratio
- Revenue Growth 5Y 11.6%
- Analyst Consensus 67% Buy
- Earnings Surprise avg 19.0%
- Share Dilution -61.5%
- Piotroski F-Score 5/9
Nicht bestanden (13)
- EPS shows upward trend
- ROIC -0.5%
- P/FCF 92.45
- P/B Ratio 3.62
- Operating Margin -0.9%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- DCF valuation (Overvalued)
- ROE -2.9%
- Net Margin Trend -2.0% vs 2.3%
Nicht verfügbar (4)
- Dividend Payout NaN%
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Gemischte Signale: Einige Bereiche bedürfen Aufmerksamkeit
Gewinnqualität
Niedrige Qualität: Rechnungslegung prüfen
Aktienverwässerung
Aktienrückkäufe. Aktionärsfreundlich
Unternehmensführung
Führungsteam
| Name | Position | Alter |
|---|---|---|
| Dr. Frank H. Laukien Ph.D. | Chairman, CEO & President | 65 |
| Dr. Mark R. Munch Ph.D. | Corporate Executive VP and President of Bruker Nano Group & Corporate | 63 |
| Dr. Falko Busse Ph.D. | President of Bruker BioSpin Group | 58 |
| Dr. Burkhard Prause Ph.D. | President and CEO of Bruker Energy & Supercon Technologies, Inc. | 58 |
Prüfungsrisiko
7
Vorstandsrisiko
6
Vergütungsrisiko
6
Aktionärsrechterisiko
4
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Latest News
Recent headlines for BRKR, sourced from Markets Gazette.